Long noncoding RNA MALAT1 may be a prognostic biomarker in IDH1/2 wild-type primary glioblastomas

Argadal, Omer Gokay; Mutlu, Melis; Aksoy, Seçil Ak; Kocaelı, Hasan; Tunca, Berrin; Civan, Muhammet Nafi; Egelí, Ünal; Çeçener, Gülşah; Bekâr, Ahmet; Taşkapılıoğlu, Mevlüt Özgür; Tekin, Çağla; Tezcan, Gülçin; Tolunay, Şahsine

doi:10.17305/bjbms.2019.4297

Cited by 6 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In their study, they found that upregulation of MALAT1 expression was associated with shorter survival rate in IDH1/2 wild-type primary glioblastoma patients, and overexpressed MALAT1 was associated with younger age and left-sided glioblastoma localization. In addition, they also reported that MALAT1 expression substantially increased in the insular lobe relative to other lobes [ 74 ]. This indicates that MALAT1 might be regard as a potential biomarker and therapeutic target in primary glioblastoma patients.…”

Section: Overview Of Long Non-coding Rnas In Glioblastomamentioning

confidence: 99%

Potential of long non-coding RNAs as a therapeutic target and molecular markers in glioblastoma pathogenesis

Chaudhary

2021

Heliyon

View full text Add to dashboard Cite

Glioblastoma (GB) is by far the most hostile type of malignant tumor that primarily affects the brain and spine, derived from star-shaped glial cells that are astrocytes and oligodendrocytes. Despite of significant efforts in recent years in glioblastoma research, the clinical efficacy of existing medical intervention is still limited and very few potential diagnostic markers are available. Long non-coding RNAs (lncRNAs) that lacks protein-coding capabilities were previously thought to be “junk sequences” in mammalian genomes are quite indispensible epigenetic regulators that can positively or negatively regulate gene expression and nuclear architecture, with significant roles in the initiation and development of tumors. Nevertheless, the precise mechanism of these distortedly expressed lncRNAs in glioblastoma pathogenesis is not yet fully understood. Since the advent of high-throughput sequencing technologies, more and more research have elucidated that lncRNAs are one of the most promising prognostic biomarkers and therapeutic targets for glioblastoma. In this paper, I briefly outlined the existing findings of lncRNAs. And also summarizes the profiles of different lncRNAs that have been broadly classified in glioblastoma research, with emphasis on both their prognostic and therapeutic values.

show abstract

Section: Overview Of Long Non-coding Rnas In Glioblastomamentioning

confidence: 99%

Potential of long non-coding RNAs as a therapeutic target and molecular markers in glioblastoma pathogenesis

Chaudhary

2021

Heliyon

View full text Add to dashboard Cite

show abstract

“…TSIX transcript, XIST antisense RNA (TSIX) is considered to orchestrate the initiation of X chromosome inactivation, thus determining which X chromosome remains active by blocking the expression of the antisense XIST RNA (27). Another lncRNA, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), was originally identified as a prognostic marker for metastatic lung cancer (28); however, it is also associated with several other human tumors, such as HCC (29) and glioblastoma (30). Therefore, the current study aimed to identify potential ncRNAs regulating PD-L1 expression in TNBC cell lines.…”

Section: Introductionmentioning

confidence: 99%

Long non‑coding RNAs XIST and MALAT1 hijack the PD‑L1 regulatory signaling pathway in breast cancer subtypes

2021

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) have attracted widespread attention as potential biological and pathological regulators. lncRNAs are involved in several biological processes in cancer. Triple negative breast cancer (TNBC) is characterized by strong heterogeneity and aggressiveness. At present, the implication of microRNAs (miRs) and lncRNAs in immunotherapy has been poorly studied. Nevertheless, the blockade of immune checkpoints, particularly that of the programmed cell-death protein-1/programmed cell-death ligand-1 (PD-L1) axis, is considered as a principle approach in breast cancer (BC) therapy. The present study aimed to investigate the interaction between immune-modulatory upstream signaling pathways of the PD-L1 transcript that could enhance personalized targeted therapy. MDA-MB-231 cells were transfected with miR-182-5p mimics followed by RNA extraction and cDNA synthesis using a reverse transcription kit, and the expression levels of the target genes were assessed by reverse transcription-quantitative PCR. Furthermore, the expression levels of target genes were measured in tissues derived from 41 patients with BC, including patients with luminal BC and TNBC, as well as their adjacent lymph nodes. The results revealed that the expression levels of miR-182-5p, PD-L1 and metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) were upregulated in MDA-MB-231 cells and BC tissues. However, X-inactive specific transcript (XIST) expression was downregulated in cancer tissues and TNBC cells. Following co-transfection of cells with small interfering RNAs specific for each target gene and miR-182-5p antagomirs, the effect of miR-182-5p was abolished in the presence of lncRNAs. Therefore, the results of the present study indicated that although miR-182-5p exhibited an oncogenic effect, XIST exerted a dominant effect on the regulation of the PD-L1 signaling pathway via the inhibition of the oncogenic function of MALAT1.

show abstract

“…DNA methylation is traditionally the most investigated epigenetic modification [ 8 ], and it can be experimentally identified in liquid biopsies. Abnormal DNA methylation may be classified as hyper- or hypomethylation.…”

Section: Introductionmentioning

confidence: 99%

Epigenetically inactivated RASSF1A as a tumor biomarker

Raos

Ulamec

Bojanac

et al. 2020

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

RASSF1A represents one of the eight isoforms of the RASSF1 gene. RASSF1A is a tumor suppressor gene whose inactivation influences tumor initiation and development. In cancer, RASSF1A is frequently inactivated by mutations, loss of heterozygosity and, most commonly, by promoter hypermethylation. As epigenetic inactivation of RASSF1A was detected in various cancer types, it was extensively investigated and nowadays, the research on RASSF1A promoter methylation proceeds in the light of an epigenetic tumor biomarker. Analyses of DNA methylation of genes involved in carcinogenesis such as RASSF1A are currently done mostly on genomic DNA (gDNA). Simultaneously, cell-free DNA (cfDNA) from liquid biopsies has lately been developed as an early cancer diagnostic tool. This review discusses the evidence on aberrantly methylated RASSF1A in gDNA and cfDNA from different cancer types and its utility for early cancer diagnosis, prognosis, and surveillance. Furthermore, methylation frequencies of RASSF1A in gDNA and cfDNA were compared in various cancer types. The weaknesses and strengths of the investigations mentioned above are discussed. In conclusion, although the importance of RASSSF1A methylation in relation to cancer was established, and it became included in several diagnostic panels, the evidence of its diagnostic utility is still experimental and not yet implemented in standard clinical health care.

show abstract

Long noncoding RNA MALAT1 may be a prognostic biomarker in IDH1/2 wild-type primary glioblastomas

Cited by 6 publications

References 26 publications

Potential of long non-coding RNAs as a therapeutic target and molecular markers in glioblastoma pathogenesis

Potential of long non-coding RNAs as a therapeutic target and molecular markers in glioblastoma pathogenesis

Long non‑coding RNAs XIST and MALAT1 hijack the PD‑L1 regulatory signaling pathway in breast cancer subtypes

Epigenetically inactivated RASSF1A as a tumor biomarker

Contact Info

Product

Resources

About